Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

被引:98
|
作者
Punt, CJA
Boni, J
Bruntsch, U
Peters, M
Thielert, C
机构
[1] Univ Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Wyeth Res, Collegeville, PA USA
[3] Klinikum Nurnberg, Nurnberg, Germany
[4] Wyeth Oncol, Munich, Germany
关键词
CCI-779; 5-fluorouracil; pharmacokinetics; phase I study; rapamycin; sirolimus; solid tumors;
D O I
10.1093/annonc/mdg248
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: CCI-779 is a novel ester of the immunosuppressive agent sirolimus that exerts cytostatic effects by the inhibition of the translation of cell-cycle regulatory proteins. We investigated the maximum tolerated dose (MTD) and pharmacokinetics (PK) of CCI-779 in combination with leucovorin (LV) and 5-fluorouracil (5-FU) in patients with advanced solid tumors. Patients and methods: Patients were treated with LV at 200 mg/m(2) as a 1-h i.v. infusion directly followed by continuous 24-h i.v. infusion of 5-FU, in the first patient at 2000 mg/m(2) and in subsequent patients at 2600 mg/m(2). CCI-779 was administered directly prior to LV as a 30-min i.v. infusion at a starting dose of 15 mg/m(2) beginning at day 8 and escalated in subsequent cohorts of patients. One cycle consisted of six weekly administrations followed by 1 week of rest. Blood samples were drawn to assess PK of CCI-779 as well as its effect on steady-state 5-FU exposures. Results: Twenty-eight patients entered the study, the majority having tumor types for which 5-FU is used as a treatment. CCI-779 doses of 15, 25, 45 and 75 mg/m(2) were investigated. Skin toxicity (rash) was prominent at all dose levels examined. Stomatitis was the dose-limiting toxicity (DLT) for 75 mg/m(2) doses of CCI-779. Subsequently the cohort at 45 mg/m(2) was expanded to a total of 15 patients, and at this dose level two treatment-related deaths occurred due to mucositis with bowel perforation. Based on the toxicities observed, it was decided to discontinue the study. Partial responses were observed in three patients with gastrointestinal tumors. No pharmacokinetic interaction between CCI-779 and 5-FU was observed. Conclusions: The safety profiles of CCI-779 and 5-FU/LV suggest an overlap of drug-related toxicities, and the administration of these drugs at these doses and schedule resulted in unacceptable toxicity and therefore cannot be recommended. If CCI-779 is to be used in combination with 5-FU/LV, other doses or schedules of administration will need to be explored.
引用
收藏
页码:931 / 937
页数:7
相关论文
共 50 条
  • [21] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cheryl D. Cho
    George A. Fisher
    Joanne Halsey
    Branimir I. Sikic
    Investigational New Drugs, 2006, 24 : 117 - 123
  • [22] Phase I and Pharmacokinetic Study of Tegafur-Uracil/Leucovorin Combined With 5-Fluorouracil/Leucovorin and Irinotecan in Patients With Advanced Colorectal Cancer
    Chayahara, Naoko
    Tamura, Takao
    Yamamori, Motohiro
    Kadowaki, Yuko
    Okuno, Tatsuya
    Miki, Ikuya
    Tsuda, Masahiro
    Nishisaki, Hogara
    Maeda, Tetsuo
    Inoue, Yoshifumi
    Okumura, Katsuhiko
    Azuma, Takeshi
    Kasuga, Masato
    Sakaeda, Toshiyuki
    Hirai, Midori
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 56 - 60
  • [23] An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer
    Caponigro, F.
    Lacombe, D.
    Twelves, C.
    Bauer, J.
    Govaerts, A. -S.
    Marreaub, S.
    Milano, A.
    Anthoney, A.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (01) : 48 - 55
  • [24] A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
    Fakih, Marwan G.
    Pendyala, Lakshmi
    Fetterly, Gerald
    Toth, Karoli
    Zwiebel, James A.
    Espinoza-Delgado, Igor
    Litwin, Alan
    Rustum, Youcef M.
    Ross, Mary Ellen
    Holleran, Julianne L.
    Egorin, Merrill J.
    CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3189 - 3195
  • [25] A phase I/pharmacologic study of UCN-01 in combination with 5-fluorouracil in patients with advanced solid tumors.
    Shah, MA
    Kortmansky, J
    Kelsen, DP
    Hseuh, C
    Kaubisch, A
    Spriggs, D
    Gonen, M
    Tong, W
    Endres, S
    Schwartz, GK
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3710S - 3710S
  • [26] Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors
    Figer, A.
    Moscovici, M.
    Bulocinic, S.
    Radu, P.
    Atsmon, J.
    Shmuely, E.
    Laba, O.
    Gadish, D.
    Brendel, E.
    Schwartz, B.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 88
  • [27] Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
    Hanauske, Axel-R.
    Cassidy, Jim
    Sastre, Javier
    Bolling, Claus
    Jones, Robert J.
    Rakhit, Ashok
    Fettner, Scott
    Brennscheidt, Ulrich
    Feyereislova, Andrea
    Diaz-Rubio, Eduardo
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 523 - 531
  • [28] Final analysis of MCO27C: a phase I trial of CCI-779 and EKB-569 in patients with advanced solid tumors
    Bryce, Alan
    Sarkaria, Jann
    Reid, Joel
    Rao, Ravi
    Qi, Yingwei
    Qin, Rui
    James, C.
    Jenkins, Robert
    Erlichman, Charles
    CANCER RESEARCH, 2009, 69
  • [29] Final analysis of MC027C: a phase I trial of CCI-779 and EKB-569 in patients with advanced solid tumors
    Bryce, Alan
    Sarkaria, Jann
    Reid, Joel
    Rao, Ravi
    Qi, Yingwei
    Qin, Rui
    James, C.
    Jenkins, Robert
    Erlichman, Charles
    CANCER RESEARCH, 2009, 69
  • [30] A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
    Zhang, Qi
    Deng, Ting
    Yang, Fen
    Guo, Weijian
    Liu, Dan
    Yuan, Jiajia
    Qi, Changsong
    Cao, Yanshuo
    Yu, Qiuqiong
    Cai, Huiming
    Peng, Zhi
    Wang, Xicheng
    Zhou, Jun
    Lu, Ming
    Gong, Jifang
    Li, Jian
    Ba, Yi
    Shen, Lin
    FRONTIERS IN PHARMACOLOGY, 2022, 13